Tenax Therapeutics (TENX) 24th Annual Needham Virtual Healthcare Conference summary

Key presentations and clinical updates

• Currently in Phase III with an oral drug for PH-HFpEF, targeting a major unmet need with no FDA-approved therapies.

• Phase III LEVEL trial expanded to 230 patients, with top-line data expected in about 18 months; a second Phase III trial is planned to start this year.

• Phase II data showed significant improvements in exercise tolerance and hemodynamics, with 29-meter gains in six-minute walk distance and meaningful reductions in wedge pressure.

• High patient retention and adherence observed in both randomized and open-label extension phases, with over 95% continuing therapy.

• The drug’s mechanism targets maladaptive venous return, addressing the core pathophysiology of PH-HFpEF.

Regulatory and trial design insights

• FDA agreed to increase trial power and patient numbers, and greenlit a second Phase III study with similar design but longer duration.

• Primary endpoint is six-minute walk distance; 25 meters is considered a conservative, clinically meaningful difference.

• KCCQ is the key secondary endpoint, accepted by FDA; NT-proBNP is included as an academic secondary endpoint.

• Safety database requirements: 300 patients for six months and 100 for 12 months of exposure.

• LEVEL trial is recruiting in the US and Canada; LEVEL 2 will expand to over 10 countries.

Market opportunity and investor perspective

• Estimated US prevalence of PH-HFpEF could reach 2.2–3.7 million by 2030, with a potential $10 billion addressable market.

• Recent funding rounds raised $100 million and $25 million, with strong backing from major investors.

• Market cap is justified at around $300 million, factoring in shares and warrants.

• Payers and physicians express strong demand for new therapies and are receptive to various price points.

• Intellectual property extends to 2040–2042, providing a long commercialization runway.